6 results on '"Grodzicki, L"'
Search Results
2. EE362 Evaluating the Cost-Effectiveness of Refluxstop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)
- Author
-
Shore, J, primary, Grodzicki, L, additional, Harper, S, additional, and Mealing, S, additional
- Published
- 2022
- Full Text
- View/download PDF
3. An Economic Evaluation of a Streamlined Day-Case Atrial Fibrillation Ablation Protocol and Conventional Cryoballoon Ablation versus Antiarrhythmic Drugs in a UK Paroxysmal Atrial Fibrillation Population.
- Author
-
Moss JWE, Todd D, Grodzicki L, Palazzolo B, Mattock R, Mealing S, Souter M, Brown B, Bromilow T, Lewis D, McCready J, Tayebjee M, Shepherd E, Sasikaran T, Coyle C, Ismyrloglou E, Johnson NA, and Kanagaratnam P
- Abstract
Background and Aims: Symptom control for atrial fibrillation can be achieved by catheter ablation or drug therapy. We assessed the cost effectiveness of a novel streamlined atrial fibrillation cryoballoon ablation protocol (AVATAR) compared with optimised antiarrhythmic drug (AAD) therapy and a conventional catheter ablation protocol, from a UK National Health Service (NHS) perspective., Methods: Data from the AVATAR study were assessed to determine the cost effectiveness of the three protocols in a two-step process. In the first stage, statistical analysis of clinical efficacy outcomes was conducted considering either a three-way comparison (AVATAR vs. conventional ablation vs. optimised AAD therapies) or a two-way comparison (pooled ablation protocol data vs. optimised AAD therapies). In the second stage, models assessed the cost effectiveness of the protocols. Costs and some of the clinical inputs in the models were derived from within-trial cost analysis and published literature. The remaining inputs were derived from clinical experts., Results: No significant differences between the ablation protocols were found for any of the clinical outcomes used in the model. Results of a within-trial cost analysis show that AVATAR is cost-saving (£1279 per patient) compared with the conventional ablation protocol. When compared with optimised AAD therapies, AVATAR (pooled conventional and AVATAR ablation protocols efficacy) was found to be more costly while offering improved clinical benefits. Over a lifetime time horizon, the incremental cost-effectiveness ratio of AVATAR was estimated as £21,046 per quality-adjusted life-year gained (95% credible interval £7086-£71,718)., Conclusions: The AVATAR streamlined protocol is likely to be a cost-effective option versus both conventional ablation and optimised AAD therapy in the UK NHS healthcare setting., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Budget Impact of RefluxStop™ as a Treatment for Patients with Refractory Gastro-oesophageal Reflux Disease in the United Kingdom.
- Author
-
Harper S, Grodzicki L, Mealing S, Gemmill E, Goldsmith P, and Ahmed A
- Abstract
Background: Gastro-oesophageal reflux disease (GORD) is a common condition associated with heartburn and regurgitation. Standard of care for GORD patients in the UK involves initial treatment with proton pump inhibitors (PPIs) and laparoscopic antireflux surgery in patients unwilling to continue or intolerant of long-term PPI treatment. Recently, RefluxStop™, a novel, implantable medical device, has proven to be an efficacious and cost-effective treatment for patients with GORD. The current analysis aimed to describe the budget impact of introducing RefluxStop™ within National Health Service (NHS) England and Wales. Objectives: To estimate the more immediate, short-term clinical and economic effects of introducing RefluxStop™ as a therapeutic option for patients with GORD treated within NHS England and Wales. Methods: A model adherent to international best practice guidelines was developed to estimate the budget impact of introducing RefluxStop™ over a 5-year time horizon, from an NHS perspective. Two hypothetical scenarios were considered, one without RefluxStop™ (comprising PPI treatment, laparoscopic Nissen fundoplication, and magnetic sphincter augmentation using the LINX® system) and one with RefluxStop™ (adding RefluxStop™ to the aforementioned treatment options). Clinical benefits and costs associated with each intervention were included in the analysis. Results: Over 5 years, introducing RefluxStop™ allowed the avoidance of 347 surgical failures, 39 reoperations, and 239 endoscopic esophageal dilations. The financial impact of introducing RefluxStop™ was £3 029 702 in year 5, corresponding to a 1.68% increase in annual NHS spending on GORD treatment in England and Wales. Discussion: While the time horizon was too short to capture some of the adverse events of PPIs and complications of GORD, such as the development of Barrett's esophagus or esophageal cancer, the use of RefluxStop™ was associated with a substantial reduction in surgical complications, including surgical failures, reoperations, and endoscopic esophageal dilations. This favorable clinical profile resulted in cost offsets for the NHS and contributed to the marginal budget impact of RefluxStop™ estimated in the current analysis. Conclusions: Introducing RefluxStop™ as a treatment option for patients with GORD in England and Wales may be associated with clinical benefits at the expense of a marginal budget impact on the NHS., Competing Interests: S.M., S.H., and L.G. work for a consulting company that works for a range of medical devices companies, including Implantica. They have no other interests to declare. E.G., P.G., and A.R.A have no interest to declare.
- Published
- 2024
- Full Text
- View/download PDF
5. Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease.
- Author
-
Harper S, Grodzicki L, Mealing S, Gemmill L, Goldsmith PJ, and Ahmed AR
- Subjects
- Humans, Cost-Benefit Analysis, Fundoplication adverse effects, Fundoplication methods, State Medicine, Treatment Outcome, Proton Pump Inhibitors therapeutic use, Quality of Life, Gastroesophageal Reflux drug therapy, Gastroesophageal Reflux surgery, Digestive System Surgical Procedures, Laparoscopy adverse effects, Laparoscopy methods
- Abstract
Aims: Gastro-esophageal reflux disease (GERD) is a common, chronic gastrointestinal condition characterized by heartburn, chest pain, regurgitation, and bloating. The current standard of care includes chronic treatment with proton pump inhibitors (PPIs) or, in selected patients, laparoscopic anti-reflux surgery. RefluxStop is a novel implantable device indicated for GERD patients eligible for laparoscopic surgical treatment. The aim of this analysis was to assess the cost-effectiveness of RefluxStop against available treatment options for GERD., Material and Methods: A Markov model was developed to assess the cost-effectiveness of RefluxStop compared with PPI-based medical management (MM) and two surgical management options, LNF and magnetic sphincter augmentation (MSA, LINX system), in people with GERD. Clinical outcomes and costs were estimated over a lifetime horizon from the UK National Health Service perspective and an annual discount rate of 3.5% was applied., Results: RefluxStop showed favorable surgical outcomes compared with both LNF and MSA. The base case incremental cost-effectiveness ratios compared with MM, LNF, and MSA were £4,156, £6,517, and £249 per QALY gained, respectively. At the UK cost-effectiveness threshold of £20,000 per QALY gained, the probability that RefluxStop was cost-effective against MM, LNF, and MSA was 100%, 93%, and 100%, respectively., Limitations: The model presented the results of a comparison, with evidence for RefluxStop derived from its single-arm CE mark trial and that for comparators from the literature. The varied clinical care pathway of individual GERD patients was necessarily simplified for modeling purposes, and necessary assumptions were made; however, the model results proved robust to sensitivity analyses., Conclusions: Introduction of RefluxStop was estimated to extend life expectancy and improve quality-of-life of GERD patients when compared with MM, LNF, and MSA. The results of the cost-effectiveness analysis demonstrated that RefluxStop is highly likely to be a cost-effective treatment option within NHS England.
- Published
- 2023
- Full Text
- View/download PDF
6. Re-designing scanning to reduce learning demands: the performance of typically developing 2-year-olds.
- Author
-
McCarthy J, Light J, Drager K, McNaughton D, Grodzicki L, Jones J, Panek E, and Parkin E
- Subjects
- Child, Preschool, Feedback, Humans, Practice, Psychological, Reference Values, Self-Help Devices, Communication Aids for Disabled, Learning
- Abstract
Children with severe motor impairments who cannot use direct selection are typically introduced to scanning as a means of accessing assistive technology. Unfortunately, it is difficult for young children to learn to scan because the design of current scanning techniques does not always make explicit the offer of items from the selection array; furthermore, it does not provide explicit feedback after activation of the switch to select the target item. In the current study, scanning was redesigned to reduce learning demands by making both the offer of items and the feedback upon selection more explicit through the use of animation realized through HTML and speech output with appropriate intonation. Twenty typically developing 2-year-olds without disabilities were randomly assigned to use either traditional scanning or enhanced scanning to select target items from an array of three items. The 2-year-olds did not learn to use traditional scanning across three sessions. Their performance in Session 3 did not differ from that in Session 1; they did not exceed chance levels of accuracy in either session (mean accuracy of 20% for Sessions 1 and 3). In contrast, the children in the enhanced scanning condition demonstrated improvements in accuracy across the three 10-20-min sessions (mean accuracies of 22 and 48% for Sessions 1 and 3, respectively). There were no reliable differences between the children's performances with the two scanning techniques for Session 1; however, by Session 3, the children were more than twice as accurate using the enhanced scanning technique compared to the traditional design. Results suggest that by redesigning scanning, we may be able to reduce some of the learning demands and thereby reduce some of the instructional time required for children to attain mastery. Clinical implications, limitations, and directions for future research and development are discussed.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.